Member Info for Shrek1st

Hi Max,

Doc Musella leaving was a massive red flag to me and then the announcement of not pursuing phase 2 of GaM was the last straw. Everything I have found about GaM suggests a positive result and helped to form a strong investment case, outweighing the obvious negatives that we have discussed ad infinitum.

The idea of concentrating on the imaging side is something we have all heard before, I remember the ‘step change’ comment. I agree the imaging products are very good but they need to translate this into revenue and quickly, there are plenty of competitors in this space.

The balance sheet is largely the result of the ill thought out decisions of two years ago, it could have been very different for everyone.

I wish you all well and hope that this turns out good. Also I hope that a properly resourced and financed organisation progresses GaM as that is the real shame here.

All the best,

Shrek

Thank you to all on this board, this investment isn’t for me anymore and I have sold my last 100k.

Good luck and I hope it turns out well for you,

Shrek

Thank you Tyke,

Shrek

Hi Tyke,

0.475 to sell.

This is a real sh@t show.

Shrek

Hi Tyke,

I hope so. I remember reading something about pancreatic cancer and a discussion regarding Gam. The technology offered by Vivan could generate some interesting results. I hope the results offer hope and new avenues for cures.

Fingers crossed,

Shrek

Hi Tyke,

I have had enough of it. I don’t expect a running commentary but some interaction with shareholders would be welcome. You make a fair point in that it has got worse and, to be fair, it was poor before that.

Shrek

Hi, I haven’t found anything else regarding the Gabriel trial.

The only thing that I turned up was this event next week, the American Society of Pediatric Neuroradiology in Tampa. Sponsored by Prism, not IB.

10:30 am - 12:00 pm

Hands-on Advanced Imaging post-processing: Sponsored by Prism

Kathleen Schmainda, PhD

Here is the link to the site:

https://aspnr.org/meetings/aspnr-annual-meeting/aspnr2026-1/8th-annual-scientific-meeting-agenda-tab-1/

Wouldn’t it be great if the company communicated with all shareholders.

Shrek

Hi Kane, that is a great find. This looks like the clinical trial record.

NCT07331064

Shrek

Part 3,

Casey Zoss

Medical College of Wisconsin, Milwaukee, USA. Dept. Biophysics, Medical College of Wisconsin, Milwaukee, USA

PresenterAuthorDDDR-61

Ferroportin-dependent iron efflux as a novel mechanism of gallium maltolate in glioblastoma

Poster and Networking Session, 11:30am-12:45pm Friday, 21 November, 2025

PresenterAuthorDDDR-58

RNA-sequencing to investigate antineoplastic mechanisms of gallium maltolate in glioblastoma

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

PresenterAuthorEXTH-134

The oral iron mimetic gallium maltolate is neurologically safe in a rat xenograft model of glioblastoma: multimodal assessment

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

Melissa Prah

Medical College of Wisconsin, Milwaukee, USA. Dept. Biophysics, Medical College of Wisconsin, Milwaukee, USA

AuthorIMG-60

Comparative evaluation of standardized relative cerebral blood volume (sRCBV) and fractional tumor burden (FTB) for predicting histologic diagnosis in brain tumors.

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

AuthorEXTH-134

The oral iron mimetic gallium maltolate is neurologically safe in a rat xenograft model of glioblastoma: multimodal assessment

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

Kathleen Schmainda

Medical College of Wisconsin, Milwaukee, USA. Dept. Biophysics, Medical College of Wisconsin, Milwaukee, USA. Dept. Radiology, Medical College of Wisconsin, Milwaukee, USA

AuthorIMG-60

Comparative evaluation of standardized relative cerebral blood volume (sRCBV) and fractional tumor burden (FTB) for predicting histologic diagnosis in brain tumors.

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

AuthorDDDR-61

Ferroportin-dependent iron efflux as a novel mechanism of gallium maltolate in glioblastoma

Poster and Networking Session, 11:30am-12:45pm Friday, 21 November, 2025

AuthorDDDR-58

RNA-sequencing to investigate antineoplastic mechanisms of gallium maltolate in glioblastoma

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

AuthorEXTH-134

The oral iron mimetic gallium maltolate is neurologically safe in a rat xenograft model of glioblastoma: multimodal assessment

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

Link:

https://virtual.oxfordabstracts.com/event/74646/submission/1654

That’s what I have found so far, I hope to have a look at some of them when I get more time. Go to say that searching within the abstract site was nice and easy for a change.

Cheers

Shrek

Part 2,

Christopher Chitambar

Medical College of Wisconsin, Milwaukee, USA. Dept. Biophysics, Medical College of Wisconsin, Milwaukee, USA. Dept. Medicine, Medical College of Wisconsin, Milwaukee, USA

AuthorDDDR-61

Ferroportin-dependent iron efflux as a novel mechanism of gallium maltolate in glioblastoma

Poster and Networking Session, 11:30am-12:45pm Friday, 21 November, 2025

AuthorDDDR-58

RNA-sequencing to investigate antineoplastic mechanisms of gallium maltolate in glioblastoma

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

AuthorEXTH-134

The oral iron mimetic gallium maltolate is neurologically safe in a rat xenograft model of glioblastoma: multimodal assessment

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

Mona Al-Gizawiy

Dept. Biophysics, Medical College of Wisconsin, Milwaukee, USA

AuthorEXTH-134

The oral iron mimetic gallium maltolate is neurologically safe in a rat xenograft model of glioblastoma: multimodal assessment

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

Okay these are by author so there are duplicates:

Jennifer Connelly

Medical College of Wisconsin, Milwaukee, USA.

AuthorIMG-96

Association of FET PET tumor volume and radio-pathomic maps of cell density in newly diagnosed glioblastoma patients

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

AuthorIMG-51

Average necrotic cell number and extracellular fluid in FLAIR regions predict survival in glioblastoma patients undergoing subtotal and gross total resection 

Rapid Orals Session III A, 11:30am-12:30pm Friday, 21 November, 2025

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

AuthorPATH-86

Demographic and morphometric features as predictors for increased SOX2 expression in non-mitotically active areas in patients with glioblastoma.

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

AuthorIMG-113

Lower DTI-ALPS Index Associates with Higher Tumor Cellularity and Contrast-Enhancing Volume in Glioblastoma

Poster and Networking Session, 11:30am-12:45pm Friday, 21 November, 2025

AuthorPATH-76

MRI-Targeted Postmortem Biopsy of Glioblastoma Using 3D-Printed Brain Cages

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

AuthorBIOM-86

Mapping Region-Specific Transcriptomic Programs in Glioblastoma from Histologically Annotated RNA-Seq Data

Cancer Neuroscience Abstracts - Session I, 10:15-11:15am Friday, 21 November, 2025

AuthorSURG-27

Prolonged tumor control in multifocal glioblastoma through a staged, multimodal therapeutic approach – a case report

Poster and Networking Session, 11:30am-12:45pm Friday, 21 November, 2025

AuthorTMOD-36

Quantifying Tumor Kinetics in Glioblastoma via Reaction-Diffusion Modeling Across Multimodal Treatment Phases using Longitudinal MRI images.

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

AuthorIMG-102

Radio-pathomic assessment of tumor dynamics following radiotherapy in glioblastoma patients

Rapid Orals Session III A, 11:30am-12:30pm Friday, 21 November, 2025

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

AuthorIMG-115

Radio-pathomic features derived non-invasively from conventional MRI differ in patients with autopsy confirmed brainstem invasion  

Poster and Networking Session, 11:30am-12:45pm Friday, 21 November, 2025

AuthorIMG-95

TTFields compliance reflects lower cellular tumor burden within contrast enhancement and FLAIR hyperintensity in glioblastoma patients 

Rapid Orals Session III A, 11:30am-12:30pm Friday, 21 November, 2025

Poster and Networking Session, 11:45am-1:05pm Saturday, 22 November, 2025

AuthorANGI-21

The Virchow-Robin space as a conduit for leptomeningeal dissemination of glioblastoma

Poster and Networking Session, 11:30am-12:45pm Friday, 21 November, 2025

AuthorEXTH-134

The oral iron mimetic gallium maltolate is neurologically safe in a rat xenograft model of glioblastoma: multimodal assessment

Poster and N

Max I meant to say that article you posted reads very well for GaM+RT as well as the safety of GaM.

Thanks

Shrek

Fingers crossed Max,

I did a search before by author and have got the titles if you want them. There are some duplicates as they appear as co authors however they have been busy. Late breaking articles don’t show in the search function.

Tyke hope you are well,

Shrek

Https://www.soc-neuro-onc.org/SNO2025/SNO2025/Home.aspx

Hello Max,

Have you seen that most of the company is attending the SNO conference this week?

The search function in the abstracts is quite good.

Shrek

Thanks Max,

The comment from Linda Herman is interesting.

Cheers

Shrek

Hi Tyke,

Looks like a sell at 0840hrs of 602150 @ 0.912.

Hope you are well

Shrek

Max that is the nail hit on the head.

When the agreement with GEHC was announced and the company products were onboarded, I thought that revenue would significantly improve. Medical sales reps are well rewarded, commissions and bonuses for hitting targets. Either there is no commercial demand for the imaging products or there is a near peer product with a higher commission.

If GEHC can’t make a sales success of IB’s products I can’t see another company fairing better, let alone the current BOD.

Sorry for being negative.

Shrek

The science behind brain cancer video MCW. Very brief mention of the phase 1 showing promise and phase 2 needed.

https://youtu.be/GdEgwJNVWZ4?si=mv0EJYWvzxFXbVgJ

Hi Tyke and Max,

This is the reference I was looking for re the breast cancer work that was grant funded last January.

Lot of information and the start date was last January, expected duration was 18 months, so possibly some findings due in a paper or presentation when the conference circuit starts again.

https://ahwendowment.org/AHW/Health-Focused-Research/Developing-a-Novel-Gallium-Compound-for-the-Treatment-of-Metastatic-Breast-Cancer.htm

Cheers

Shrek